Featured Video

European Academy of Neurology (EAN) and Peripheral Nerve Society (PNS) Guideline on diagnosis and treatment of chronic inflammatory demyelinating polyradiculoneuropathy: Report of a joint Task Force—Second Revision

  • CIDP

Watch Dr. Peter Van den Bergh, lead author, take you through the highlights of the guideline.

Videos about CIDP

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
3:00 MIN
  • CIDP
  • MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

DOWNLOAD PDF
Pathogenesis and Mechanism of Action of Inflammatory Neuropathies
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
13:53 MIN
  • CIDP
  • GBS
  • MMN

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

DOWNLOAD PDF
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy
Mel Berger, MD, PhD
Medical Research Strategy, CSL Behring
8:25 MIN
  • CIDP

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

DOWNLOAD PDF
Clinical Studies for the Treatment of CIDP with Immunoglobulin
Claudia Sommer, MD
University of Würzburg, Würzburg, Germany
9:35 MIN
  • CIDP

Learn about clinical studies for the treatment of CIDP with immunoglobulin.

DOWNLOAD PDF
NOW PLAYING
3:00
Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic...

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

NOW PLAYING
13:53
Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

NOW PLAYING
8:25
Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Th...

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

NOW PLAYING
9:35
Clinical Studies for the Treatment of CIDP with Immunoglobulin

Learn about clinical studies for the treatment of CIDP with immunoglobulin.

Our Experts on CIDP

Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
Richard A. Lewis, MD
Richard A. Lewis, MD
Cedars-Sinai Medical Center, Los Angeles, CA, USA
  • CIDP
  • GBS
  • MMN
Richard A. Lewis, MD is Professor of Neurology at Cedars-Sinai Medical Center in Los Angeles, California where he directs the EMG laboratory and co-directs the neuromuscular clinical program.
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
Peter Van den Bergh, MD PhD
Van den Bergh, MD PhD
University Hospital Saint-Luc, Brussels, Belgium
  • CIDP

Peter Van den Bergh is Professor of Neurology at the Université Catholique de Louvain and Director of the Neuromuscular Centre of Reference of the Cliniques Universitaires Saint-Luc, Brussels, Belgium.

Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
Nabil Moumane, MD
Nabil Moumane, MD
Medical Affairs and Pharmacology, CSL Behring
  • CIDP
  • MMN
Nabil Moumane is the Director of Medical Affairs and Pharmacology at CSL Behring.
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
Vera Bril, BSc, FRCPC, MD
Vera Bril, BSc, FRCPC, MD
University of Toronto,Toronto, Canada
  • CIDP
Vera Bril is a Professor of Medicine (Neurology) at the University of Toronto, Director of Neurology at University Health Network and Mount Sinai Hospital and the Krembil Family Chair in Neurology.
What is Chronic Inflammatory
Demyelinating Polyneuropathy (CIDP)?
READ MORE
What are the symptoms of CIDP?
READ MORE
How is CIDP treated?
READ MORE

Slides & Posters about CIDP

Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations
PDF | 2.2 MB
Fatigue in CIDP
PDF | 1.23 MB
Optimizing IgG Therapy in Chronic Autoimmune Neuropathies
PDF | 3.4 MB
Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study
PDF | 0.98 MB
Back to Top